Trial of Laryngeal Preservation Comparing Induced CT Followed by RT vs CT Concomitant to RT

Inclusion Criteria: * Squamous cell carcinoma of the larynx or hypopharynx, histologically proven, locally advanced: * T2 not accessible to a supra-cricoid partial laryngectomy or not, * T3 without massive infiltration by endolarynx transglottic injury, * N0 to N2c * No distant metastasis * No associated cancer or earlier * Patients Previously Untreated * Age\> 18 years and \<75 years * PS 0 or 1 according to WHO * Tumor volume assessable by RECIST. * Absence of distant metastasis, confirmed by chest TDM, abdominal ultrasound (or TDM) in case of abnormal liver function and bone scan if local symptoms. * Absence of any participation in a clinical trial within 30 days prior to inclusion. * Absence of any concomitant cancer treatment. * Absence of any chronic treatment ( ≥3 months) with a daily corticosteroid dose is ≥20 mg / day of methylprednisolone or equivalent. * Hematological function: neutrophils ≥1.5 x 109 / L, platelets ≥100 x 109 / l, hemoglobin ≥10 g / dl (or 6.2 mmol / l). * Hepatic function: normal total bilirubin; AST (SGOT) and ALT (SGPT) ≤ 2.5 x ULN (LNS) of each center; alkaline phosphatase ≤ 5 x LNS. * Renal function: serum creatinine ≤ 120 mol / l (1.4 mg / dl); if creatinine \> 120 mol / l, creatinine clearance should be ≥ 60 ml / min. * calculated creatinine clearance (Crockcroft formula) or measured ≥ 60 ml / min * Estimated life expectancy ≥ 3 months * Weight loss less than 10% over the last 3 months * Patient has given its written consent before any specific procedure of the Protocol. * Women and men of childbearing age should have accepted a medically effective contraception during the treatment period and at least 6 months after discontinuation of study treatments (Docetaxel, 5-Fluorouracil and Cisplatin. If pregnancy is declared by a patient or partner of a patient, it must be followed to know the evolution of pregnancy. Exclusion Criteria: * transglottic T3 with massive infiltration of hemilarynx or T4 with massive cartilaginous tumor lysis or reverse cricoarythénoïdenne region or posterior hypopharyngeal wall * tumor requiring the completion of an immediately tracheotomy. * Tumour available immediately to partial surgery. * tumor requiring circular hypopharyngectomie * N3 nodal injury * Vaccination against yellow fever recent or anticipated * Deficit known dihydropyrimidine dehydrogenase (DPD) * Other malignancies within 5 years prior to randomization, with the exception of adequately treated basal skin cancer and carcinoma in situ of the cervix. * Patients with AST or ALT\> 1.5xULN associated with alkaline phosphatase \> 2.5x LNS will not be eligible for testing. * symptomatic neuropathy grade ≥2 with NCI-CTC. * Clinical alteration of hearing function. * Other concomitant serious medical conditions (partial list): * Unstable cardiac disease despite treatment. * Myocardial infarction within 6 months prior to trial entry. * Neurological or psychiatric history such as dementia, seizures; * Severe uncontrolled infection. * Significant gastrointestinal abnormalities, including those that require parenteral nutrition, active peptic ulcer disease and a history of surgical procedures affecting absorption * Obstructive pulmonary disease requiring hospitalization in the year before inclusion. * Unstable diabetes or other cons-indications to corticosteroids. * Significant ophthalmologic abnormality. * Moderate or severe eczema. * Allergy to iodine. * Hypersensitivity to Docetaxel, Cisplatin or at one of their excipients. * Concomitant use of phenytoin, carbamazepine, barbiturates and rifampicin. * Presence, selection, psychological factors, family, social or geographical may alter patient compliance with the study protocol and follow-up, a criterion of non-inclusion. These factors should be discussed with the patient before inclusion in the trial. * Pregnant or nursing women. * Patient (male or female) of childbearing age not taking adequate contraceptive measures. * Patient deprived of their liberty, without guardianship or curatorship.